Core Points - The 8th China International Import Expo (CIIE) will officially accept registrations for domestic and international professional visitors starting June 6, 2025, with the event scheduled from November 5 to 10, 2025, at the National Exhibition and Convention Center in Shanghai [1] - The expo will feature six major exhibition areas including medical devices and healthcare, automotive and smart mobility, technological equipment, consumer goods, agricultural products, and service trade, along with an innovation incubation area [1] - The national comprehensive exhibition has begun inviting countries and international organizations to participate, with nearly 800 companies from over 70 countries already signed up, covering an exhibition area of nearly 250,000 square meters [2] Company Highlights - Sanofi has confirmed its participation for the eighth consecutive year, focusing on innovations in immunology and plans to showcase new drugs and vaccines, reinforcing its commitment to the Chinese market and patients [2] - Sanofi's ongoing participation reflects confidence in the Chinese economy and the CIIE, with the company emphasizing its long-term commitment to contributing to the "Healthy China" initiative [2] Industry Impact - Since its inception in 2018, the CIIE has attracted over 180 countries and regions, with approximately 23,000 foreign exhibitors showcasing nearly 3,000 new products, technologies, and services, resulting in an intended transaction amount exceeding $500 billion [3] - The event has registered nearly 2.9 million professional visitors and organized over 1,200 supporting activities and 1,300 cultural exchange events, highlighting its significance in promoting international trade and cooperation [3]

Core Viewpoint - Sanofi is showcasing its innovative products at the 2025 China Beijing International Science and Technology Industry Expo, emphasizing its commitment to advancing immunology and local healthcare integration in China [1][2] Group 1: Company Strategy - China is Sanofi's second-largest market, and the company is accelerating the introduction of over 60 innovative drugs and vaccines in the country [1][2] - Sanofi has established four local R&D centers in Beijing, Shanghai, Chengdu, and Suzhou, contributing to over 90% of its global R&D projects [2] Group 2: Collaboration and Partnerships - Sanofi collaborates with local biopharmaceutical companies like Jixing Pharmaceutical and Tianjing Biotech to advance research in oncology and immunology [2] - The company has formed a specialized pharmaceutical innovation fund with KKR to expedite the commercialization of local research outcomes [2] Group 3: Production and Supply Chain - Sanofi has developed a large-scale local production and supply network covering the Beijing-Tianjin-Hebei, Yangtze River Delta, and Greater Bay Area [2] - The Beijing production base in Yizhuang is the largest insulin injection production facility for Sanofi in the Asia-Pacific region [2]

Group 1 - The 2025 Beijing International Technology Industry Expo focuses on strategic emerging industries, particularly biomedicine, showcasing the achievements of Beijing's international technology innovation center [1] - Sanofi highlights its commitment to immunology innovation and local scientific ecosystem development, presenting nine breakthrough therapies across key disease areas [1] - Sanofi has introduced over 60 innovative drugs and vaccines to China, addressing seven of the top ten deadly diseases in the country [1] Group 2 - China is Sanofi's second-largest market, with over 90% of its global R&D projects involving Chinese participation, establishing China as a critical component of Sanofi's global R&D strategy [2] - Sanofi collaborates with leading local biopharmaceutical companies to accelerate the development of cutting-edge therapies in oncology and immunology [2] - The company has established a special pharmaceutical innovation fund in partnership with KKR to facilitate the commercialization of local research achievements [2] Group 3 - In December 2024, Sanofi announced a €1 billion investment to build an insulin production facility in Beijing, marking the largest single investment by the company in China [3] - Sanofi has developed a large-scale local production and supply network covering key regions in China, including Beijing-Tianjin-Hebei, the Yangtze River Delta, and the Greater Bay Area [3] - The company aims to strengthen its integrated industrial chain from R&D to production and operations in China, enhancing local healthcare development [3]

Core Viewpoint - Sanofi showcased its global innovative products at the 2025 Beijing International Technology Industry Expo, emphasizing its commitment to the Chinese market and its role in advancing the local biopharmaceutical ecosystem [1][3]. Group 1: Company Strategy and Market Position - Sanofi focuses on immunology innovation, presenting nine breakthrough therapies addressing key disease areas such as respiratory diseases, skin immunity, and metabolic diseases [3]. - The company has introduced over 60 innovative drugs and vaccines to China, covering seven of the top ten deadliest diseases in the country, thereby addressing unmet medical needs [3]. - China is Sanofi's second-largest market, and the company aims to leverage global resources to enhance local practices and accelerate the translation of pharmaceutical innovations [3]. Group 2: Research and Development - Sanofi has established four local R&D centers in Beijing, Shanghai, Chengdu, and Suzhou, creating a nationwide research network [3]. - Over 90% of Sanofi's global R&D projects involve China, highlighting the country's significant role in the company's innovation capabilities [3]. Group 3: Local Partnerships and Collaborations - Sanofi collaborates with leading local biopharmaceutical companies such as Jinxing Pharmaceutical and Tianjing Biotech to advance research in oncology and immunology [3]. - The company has formed a specialized pharmaceutical innovation fund with KKR to accelerate the commercialization of local research outcomes [3]. - Sanofi actively explores innovative business models with industry partners like Shanghai Pharmaceuticals to improve accessibility to primary healthcare services [3]. Group 4: Manufacturing and Investment - Sanofi has developed a large-scale local production and supply network covering the Beijing-Tianjin-Hebei, Yangtze River Delta, and Greater Bay Area [4]. - The Beijing production base, designed to international standards, is the largest insulin injection production facility in the Asia-Pacific region [4]. - In December 2024, Sanofi announced a €1 billion investment to establish a new insulin production base in Beijing, marking the company's largest single investment in China [4].